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Abstract
Vascular hyperpermeability is a frequent intractable feature involved in a wide range of diseases in the
intensive care unit. The glycocalyx (GCX) seemingly plays a key role to control vascular permeability. The GCX
has attracted the attention of clinicians working on vascular permeability involving angiopathies, and several
clinical approaches to examine the involvement of the GCX have been attempted. The GCX is a major
constituent of the endothelial surface layer (ESL), which covers most of the surface of the endothelial cells
and reduces the access of cellular and macromolecular components of the blood to the surface of the
endothelium. It has become evident that this structure is not just a barrier for vascular permeability but
contributes to various functions including signal sensing and transmission to the endothelium. Because GCX is
a highly fragile and unstable layer, the image had been only obtained by conventional transmission electron
microscopy. Recently, advanced microscopy techniques have enabled direct visualization of the GCX in vivo,
most of which use fluorescent-labeled lectins that bind to specific disaccharide moieties of glycosaminoglycan
(GAG) chains. Fluorescent-labeled solutes also enabled to demonstrate vascular leakage under the in vivo
microscope. Thus, functional analysis of GCX is advancing. A biomarker of GCX degradation has been clinically
applied as a marker of vascular damage caused by surgery. Fragments of the GCX, such as syndecan-1 and/or
hyaluronan (HA), have been examined, and their validity is now being examined. It is expected that GCX
fragments can be a reliable diagnostic or prognostic indicator in various pathological conditions. Since GCX
degradation is strongly correlated with disease progression, pharmacological intervention to prevent GCX
degradation has been widely considered. HA and other GAGs are candidates to repair GCX; further studies are
needed to establish pharmacological intervention. Recent advancement of GCX research has demonstrated
that vascular permeability is not regulated by simple Starling’s law. Biological regulation of vascular
permeability by GCX opens the way to develop medical intervention to control vascular permeability in
critical care patients.
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Background
More than 70 years ago, Danielli [1] and Chambers and
Zweifach [2] introduced the concept of a thin non-
cellular layer on the endothelial surface. This layer was
thought to include absorbed plasma protein, although a
direct demonstration of this layer was technically impos-
sible at that time. About 20 years later, Copley [3] re-
ported the endothelium–plasma interface and developed
a concept in which the endothelial surface was covered
by a thin molecular layer and an immobile sheet of
plasma. The existence of the latter structure was identi-
fied when intravital microscopy was used to examine the
hamster cheek pouch. In 1966, Luft used ruthenium red
staining and electron microscopy to examine the endo-
thelial surface [4]. Using this technique, Luft directly
demonstrated the existence of an endocapillary layer that
had evaded visualization using light or electron micros-
copy; this layer had a thickness in the range of 20 nm.
Subsequent studies replicated these results and led to the
concept that this layer was composed of proteoglycans
(PGs) and glycosaminoglycans (GAGs) with a thickness of
several tens of nanometers, as has been previously
reviewed [5, 6]. Since the 1970s, the development of the
intravital model for studying microcirculation has enabled
several indirect and direct observations of the existence of
an endothelial surface layer with a gel-like endothelial gly-
cocalyx layer (GCX) located on the luminal surface of
blood vessels [5].
Biology of glycocalyx
Structure of the endothelial GCX
The endothelial surface layer (ESL) is a multilayer struc-
ture that normally covers most of the surface of the
endothelial cells and reduces the access of cellular and
macromolecular components of the blood to the surface
of the endothelium. The GCX, which is major constitu-
ent of the ESL, forms a luminal mesh that provides
endothelial cells with a framework to bind plasma pro-
teins and soluble GAGs. The GCX itself is inactive; how-
ever, once plasma constituents are bound with or
immersed into the GCX, it forms the physiologically ac-
tive ESL [7] (Fig. 1).
Glycoproteins and PGs form the bulk of the GCX [5,
8, 9]. PGs have a protein core to which are attached
negatively charged GAG side chains. These PGs vary in
the size of their core proteins, the number of GAG side
chains, and their binding to the cell membrane (Table 1).
The most common GAG (50–90 %) in the vascular sys-
tem is heparan sulfate (HS) [10, 11], with the remainder
composed of hyaluronic acid and chondroitin, dermatan,
and keratan sulfates. HS is found on several core pro-
teins including perlecan, glypican, and syndecans. Perle-
can is a large HS proteoglycan found in the basement
membrane. Glypicans are a family of cell surface HS
proteoglycans having a glycosylphosphatidylinositol an-
chor [12, 13]. The syndecan family consists of trans-
membrane proteoglycans found in the GCX that are
shed in a soluble form when the GCX becomes disor-
dered. Each syndecan consists of an extracellular domain
that contains GAG attachment sites, a single pass trans-
membrane domain, and a short cytoplasmic domain
with phosphorylation sites. Other core proteins, such as
versicans, decorins, biglycans, and mimecans, are chon-
droitin sulfate-bearing or dermatan sulfate-bearing proteo-
glycans [11, 14]. On the other, hyaluronic acid is a GAG
that does not have the ability to bind to a protein core.
The composition and dimensions of the GCX fluctuate
as it continuously replaces material sheared by flowing
plasma [15], while throughout the vasculature, the thick-
ness varies tenfold from several hundreds of nanometers
to several micrometers [8]. The GCX forms a luminal
mesh that provides endothelial cells with a framework to
bind plasma proteins and soluble GAGs [16, 17].
Physiological function of the ESL
Vascular permeability barrier
The ESL and the GCX regulate vascular permeability
[18]. The charged and complexed mesh structure of the
GCX acts as a macromolecular sieve [16], repelling
negatively charged molecules as well as white and red
blood cells and platelets. For example, macromolecules
larger than 70 kDa are known to be excluded from the
GCX. Albumin is 67 kDa and has a net negative charge
but binds tightly to the GCX [5] because of its
Fig. 1 Structural diagram of the ESL. The ESL is composed of a layer of PGs and GAGs lining the luminal surface of the endothelium. The image
is not shown to scale
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amphoteric nature (it carries some positive charges
along the protein chain). This binding reduces the hy-
draulic conductivity across the vascular barrier; there-
fore, some albumin leaks through the GCX [19]. Some
pathophysiological statuses that are accompanied by the
disruption of the GCX can lead to hyperpermeability.
Mechanotransduction
The GCX also acts as a mechanotransducer, transmit-
ting shear stress forces to endothelial cells thorough
its intracellular protein domain [8, 18]. Conform-
ational changes in the GCX, which can be induced by
blood flow, trigger the release of nitric oxide, thereby con-
tributing to the regulation of vasomotor tone and the per-
ipheral distribution of oxygen. The GCX thus contributes
to the maintenance of homeostasis in the peripheral tis-
sues through this rheological mechanism [20].
Vascular protection via the inhibition of coagulation and
leukocyte adhesion
The GCX has been shown to be a significant binding site
for blood proteins, such as antithrombin III, fibroblast
growth factor, and extracellular superoxide dismutase.
Based on these interactions, the most important physio-
logical role of the endothelial GCX is vascular protection
via the inhibition of coagulation and leucocyte adhesion
[21, 22].
Cell adhesion molecules on the endothelium, such as
integrins and immunoglobulins, are buried deep within
the ESL. Under inflammatory conditions, the activation
and/or externalization of proteases or glycosidases can
lead to the degradation of the GCX through the diges-
tion of PGs and/or GAGs. Shedding of the GCX may fa-
cilitate ligand-receptor interactions that promote the
adhesion of leukocytes [23].
Research methods
Ultrastructure observation by electron microscopy
The first image of the endothelial GCX was obtained
using conventional transmission electron microscopy
(TEM), which revealed a small layer approximately
20 nm thick in capillaries [4]. Since then, several TEM
approaches, along with various perfusates or fixatives,
have demonstrated stained GCX structures with large
variations in thickness [16, 24]. When fixation tech-
niques were applied to stabilize and prevent the loss of
negatively charged structures, such as lanthanum [25],
evidence of a thick ESL (up to approximately 800 nm in
width) was obtained [26, 27]. Lanthanum clearly stains
the hair-like structure of GCX, which enables to
measure the thickness of the GCX (Fig. 2). The dif-
ferences in GCX thicknesses and structures can likely
be attributed to the use of different TEM approaches
and fixation methods (perfusion or immersion). The
use of alcohol during specimen processing can led to
the considerable collapse of the dehydrated gel-like
state of the GCX and replacement with organic sol-
vents. To avoid shrinkage by dehydration, Ebong et
al. used rapid freeze technique to preserve the native
state of the GCX structure, which preserves a high
water content, with which thicknesses were quantified
as 6 μm for rat fat pads and 11 μm for bovine aorta
[28]. The thickness of GCX may be longer than ever
expected. The measurement of thickness is also
largely different between visualization techniques.
Table 1 Characterization of proteoglycan core proteins in glycocalyx
Core protein Core size (kDa) Number of subtype Structure characteristic Linked GAG
Syndecan 19–35 4 Transmembrane protein HS, CS
Glypican 57–69 6 GPI-anchored protein HS, CS
Perlecan 400 1 Secreted HS, CS
Versian 370 1 Secreted CS, DS
Decorin 40 1 Secreted CS, DS
Biglycan 40 1 Secreted CS, DS
Minecan 35 1 Secreted KS
HS heparan sulfate, CS chondroitin sulfate, DS dermatian sulfate, KS keratan sulfate
Fig. 2 GCX layer visualized using transmission electron microscopy.
Mice were fixed by perfusion with glutaraldehyde-lanthanum
solution. The photos show a post-capillary venule under normal
conditions. (The image was originally obtained by H. Kataoka)
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Visualization by intravital microscopy
Direct visualization of the GCX can be performed using
several approaches, most of which use fluorescent-
labeled lectins that bind to specific disaccharide moieties
of GAG chains [29].
It has been examined a variety of fluorescent-labeled
lectins for visualizing the ESL in vivo using fluorescence
microscopy and shown that the specific binding of FITC
(fluorescein isothiocyanate)-labeled WGA (wheat germ
agglutinin) to the luminal surface of the vessel could be
appropriately monitored in a mouse dorsal skinfold win-
dow [30, 31].
Recently, a novel technique that directly visualizes lar-
ger vessels using a two-photon laser scanning micro-
scope (TPLSM) enabled a detailed description of the
endothelial surface and the identification of the GCX
[32, 33] because of its enhanced penetration depth, good
resolution, and optical sectioning. It has been reported
that thickness of the GCX of intact mouse carotid arter-
ies was 4.5 μm by means of this technique [11].
Functional analysis
Leukocyte-endothelial interactions
Although the morphological profile of the GCX has begun
to be elucidated, functional analyses are now needed to
clarify the roles of the GCX. Receptors on the surface of
the endothelium are assumed to hinder behind the GCX,
and the degradation of the GCX exposes these receptors
and triggers leukocyte-endothelial interactions. Lipopoly-
saccharide (LPS) may be a useful tool for triggering GCX
degradation [34]. GCX degradation leads exteriorization
of ICAM-1 (intercellular adhesion molecule 1) and/or
VCAM-1 (vascular cell adhesion molecule 1) to the lumen
of vasculature, which enhances leukocyte-endothelial in-
teractions [35, 36]. The rolling leukocyte on the vessel wall
is visualized in the septic model where the leukocyte is la-
beled with rhodamine 6G (Fig. 3a).
The heparanase-mediated mice also lose the ESL,
which leads to the exposure of ICAM-1, VCAM-1 to
circulating activated neutrophils, facilitating their adher-
ence and extravasation [22, 37, 38]. Increases in the ex-
pressions of E-selectin, ICAM-1, and VCAM-1 have
been reported in human microvascular endothelial cells
[39, 40] and mice [41]. Although the importance of the
GCX is being recognized, further study is needed to clar-
ify the integrated mechanisms involved in the loss of the
GCX and leukocyte-endothelium interactions.
Vascular permeability
Another functional role of the GCX is as a barrier to vas-
cular permeability. To observe changes in vascular perme-
ability in vivo, a dye extraction method, such as the Evans
blue method, has been used [42]. However, with the devel-
opment of fluorescent imaging, the use of dextran
covalently linked to a fluorophore has become the stand-
ard technique for qualifying and quantifying vascular per-
meability. In some studies, FITC-labeled bovine serum
albumin (BSA; molecular weight, 66 kDa) has been used
to determine the vascular permeability in rodent chamber
models. As a substitute for BSA, dextran, a molecular
weight of 70 kDa has also been used extensively, since it
has a similar molecular weight. In a study performed by
Alfieri [43], they used FITC albumin, and its leakage was
quantified by using the alteration of fluorescence in the
ROIs (region of interests) consisted of defined squares of
900 μm2 (30 × 30 μm) located in three distinct interstitial
areas. This technique can be applied to various weights of
molecules. Kataoka and colleagues modified this method;
FITC-labeled dextran (70 kDa) was injected intravenously
in the mouse model, and the fluorescent intensity in ROIs
(30 × 30 μm; Fig. 3b) using intravital microscopy was
monitored. The data enabled the quantitative and con-
tinuous analysis of permeability under septic conditions
(Kataoka et al., submitted).
Pathophysiologies involving the GCX
Revised Starling’s law
The GCX layer and its mechanism for controlling fluid
movement
The GCX covers the luminal surface of the endothelium,
which sieves molecules to the interstitium. The sub-GCX
space in the intercellular cleft also forms a buffer space for
molecules from the interstitium and intravascular spaces.
This fragile and tiny structure acts as a barrier for the ves-
sels. Studies on microvascular fluid exchange have
attempted to estimate the accurate Pc (hydrostatic pres-
sure) and π (osmotic pressure) and have revealed that the
Fig. 3 Typical experimental methods used to analyze GCX/ESL
function. a Fluorescent-labeled leukocytes in microvasculature. To
quantify the leukocyte-endothelium interaction, fluorescence-labeled
leukocytes in flowing blood were observed within a region of
interest (ROI) during a 30-s video recording, and adhesive and/or
rolling leukocytes were counted. b Permeable analysis using FITC
dextran. To analyze vascular permeability, fluorescence-labeled
dextran was injected and time-dependent changes in brightness
within an ROI (yellow box) set over the interstitium were identified
using image analysis software. (These images were originally obtained
by H. Kataoka)
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sub-GCX π is lower than the interstitial π. This means
that the lower π space in the intercellular cleft insulates
fluid movement along the osmotic gradient.
Based on these findings, Starling’s law for fluid move-
ment was revised [44, 45]. According to the revised
Starling’s principle, capillary hydrostatic pressure is the
dominant factor in determining filtration and absorption
(Fig. 4). Even at a low capillary pressure, absorption
rarely occurs, and water movement is unidirectional. Under
septic conditions, the profile for large pore filtration in-
creases as the capillary pressure increases; this explains why
fluid leakage is enhanced under septic conditions.
Pathological alterations
GCX degradation and hyperpermeability
The GCX layer rarely allows water leakage through the
ETC. However, once the GCX is disrupted, the permeabil-
ity of the endothelial cells increases dramatically. Hyper-
permeability induced by sepsis is a typical example in
which GCX damage induces macromolecule leakage.
However, the denudation of the vascular inner lumen
itself cannot explain the leakage of water and other mole-
cules, since endothelial cells bind tightly with neighboring
cells via specific proteins, including cadherin and claudin
[46, 47]. Therefore, the mechanism by which GCX deg-
radation results in vascular hyperpermeability needs to be
established. There are two pathways for the leakage of
water and other molecules. The ETC has been suggested
as one possible pathway and has been named the para-
cellular pathway [44]. This pathway requires the opening
of intercellular keys, the proteins of which are known as
tight junctions, adherent junctions, and gap junctions.
This pathway seems to require intracellular signal conduc-
tion to loosen these junctions. A transcellular pathway has
also been suggested. Vesicular transport to the interstitium
has been confirmed during sepsis. The transcellular trans-
port of macromolecules also results in interstitial edema.
GCX and vascular contraction
The GCX has been shown to sense blood flow and to
regulate vascular tone via the production of NO (nitric
oxide).
Fig. 4 Steady-state fluid exchange simulated for a post-capillary venule, with the fluid-conducting pathways modeled as parallel small pore and
large pore populations, under normal and inflamed conditions. a Basal low permeability state: 95 % of the hydraulic conductance is represented
by small pores (radius = 4 nm; blue curve) and 5 % is represented by large pores (radius = 22.5 nm; red curve). The black solid curve shows the total
fluid exchange (sum of the red and blue lines) at varying values of Pc. The vessel was perfused with Ringer solution containing serum albumin
(Πp = 25 cmH2O). Pi was assumed to be constant, and the aquaporin pathway was negligible (≤10 % of total conductance). b Steady-state fluid
exchange under increased permeability conditions in the same vessel as that shown in a. The red curve represents the flow through the large pore
system after inflammation had increased the number of large pores by tenfold. The small pore population remained unchanged. The dashed lines
represent extrapolations of the linear parts of the steady-state summed relations to the pressure axis, where their intersection gives the
value of the effective COP opposing fluid filtration (reduced during inflammation). The vertical arrows show the typical microvascular
pressures under the basal condition (A) and during mild inflammation (b). The increase in pressure contributed to the dramatic 17-fold
increase in the filtration rate (cited from Levick JR, Michel CC. Cardiovasc Res. 2010;87(2):198–210.)
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Yen et al. demonstrated that the denudation of the
GCX by heparinase III reduced NO production; thus,
the GCX has a physiological role in mechanosensing
[48, 49], which may have an important role in the devel-
opment of angiopathies and arteriosclerosis. According
to the proposed hypothesis, GAGs holds negatively
charged HS and consists of the structured water area.
This area excludes the blood stream and protects the
endothelial surface from being damaged. Positively
charged cells or substances streaming in a column of
negative charges create an electromagnetic field, result-
ing in the production of NO [50]. NO physiologically di-
lates vessels; if the dilation is sustained pathologically,
NO further triggers free radicals and disrupts the ESL
[51]. This disruption was suggested to trigger cholesterol
accumulation, resulting in arteriosclerosis. Since the
GCX is an insulator, this hypothesis is convincing. Fur-
ther study may unveil the mechanism responsible for
vascular aging, which would promote additional investi-
gations of the GCX.
Clinical implications
Clinical monitoring of the GCX
Angiopathy is a frequent pathological feature involved in
a wide range of diseases. The GCX has attracted the at-
tention of clinicians working on angiopathies, and sev-
eral clinical approaches to examining the involvement of
the GCX have been attempted. A biomarker of GCX
degradation has been clinically applied as a marker of
vascular damage caused by surgery. Fragments of the
GCX, such as syndecan-1 and/or hyaluronan (HA), have
been examined, and their validity is now being exam-
ined. Various clinical studies have also been reported.
The GCX is assumed to act as a size barrier for albu-
min filtration. Thus, GCX fragments could be a bio-
marker of renal disease [52]. Plasma HA is increased in
patients with chronic kidney disease [53], kidney failure,
hemodialysis, or peritoneal dialysis [54]. Whether this
change should be interpreted as indicating degradation
or increased turnover remains uncertain. However, a
high concentration of HA seems to be a predictor of
survival [55]. Acute decompensated heart failure
(ADHF) is closely associated with AKI (acute kidney in-
jury) [56]. Syndecan-1 has been assumed to be a pre-
dictor of death from ADHF [56], and syndecan-1 was
selected as a significant predictor (odds ratio, 1.461;
95 % confidence interval, 1.256–1.677). In addition, bio-
markers of the GCX are also being considered as pos-
sible indicators of the prognosis and diagnosis of various
other diseases. Positive associations with these bio-
markers have already been demonstrated for diabetes
mellitus [57], cardiac surgery [58], Alzheimer disease
[59], hematological disease [60, 61], and Crohn’s disease
[62] (Table 2). Thus, damage to the GCX, as reflected by
the plasma syndecan-1 concentration, is attracting atten-
tion in critical care fields. Even transfusions could poten-
tially damage the GCX. Larsen demonstrated that the
expression of syndecan-1 increased 24 h after red blood
Table 2 Clinical assessments of GCX damage
Fragment detection
Authors Subjects Substances Results
Ostrowski [65] Trauma Soluble VEGF receptor 1 Positive correlation with injury severity
Padberg [53] CKD Syn-1, HA, sFlt-1, sVCAM-1, vWF,
angiopoietin-2
Syn-1, HA increased in parallel with CKD stage
Larsen [60] RBC transfusion Syn-1, slCAM-1, sVE-cadherin,
hyaluronan
Slight increase in syn-1 at 24 h after transfusion
Larsen [61] Myeloid leukemia Syn-1, slCAM-1, sVE-cadherin, hyaluronan High syn-1 was associated with bleeding,
impaired platelet function
Neves [56] Acute decompensated heart failure Syn-1 Syn-1 was high in AKI
Cekic [62] Crohn’s disease Syn-1 Disease activity was correlated with syn-1
Page [63] (review) Infectious disease Ang-1,-2, vWF, thrombomodulin,
sE-selectin, slCAM-1, sVCAM-1




Nussbaum [57] Children, diabetes mellitus type 1 GCX thickness was inversely correlated with
glucose
Koning [68] Cardiac surgery Pulsatile and non-pulsatile reduced perfusion
density zone
Broekhuizen [67] Diabetes mellitus type 2 Sulodexide increased GCX thickness
syn-1 syndecan-1, HA hyaluronan, sFlt-1 soluble fms-like tyrosine kinase-1, sVCAM-1 soluble vascular adhesion molecule-1, vWF von-Willebrand factor, sVE-cadherin
soluble vascular endothelial cadherin
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cell or platelet transfusion in patients with hematological
disease [60]. This data suggests that the detection of
GCX fragments may indicate physiological turnover of
the GCX. Finally, Page et al. reviewed the clinical utility
of various endothelial biomarkers for infectious disease
[63] and concluded that so far, none of the examined
biomarkers are clinically useful as a reliable diagnostic
or prognostic indicator in sepsis.
The GCX covers various receptors on the endothelial
surface. Vascular endothelial growth factor (VEGF) is an
important regulator of angiogenesis as well as perme-
ability and vasodilation. This factor binds two types of
receptors: VEGFR1 and VEGFR2. The binding of these
receptors is regulated by soluble Fms-like tyrosine kinase
receptor (sFlt-1). Reportedly, elevations in sFlt-1 are
closely correlated with the APACHE II (Acute Physi-
ology and Chronic Health Evaluation II) score, and the
sFlt-1 level might be useful as a predictor of survival
[64]. This receptor fragment on the endothelial surface
is conceivably induced by GCX degradation. Actually, a
close association has been shown between an elevation
in syndecan-1 and the sVEGFR1 level (r = 0.76, P <
0.001) [65]. The appearance of this receptor fragment in
the blood may reflect the extent of GCX degradation.
The diameters of peripheral vessels can be measured
microscopically. The GCX layer covers the luminal sur-
face, and red blood cells cannot pass through this layer.
Consequently, visualization of the red blood cell stream
Fig. 5 Sidestream dark field (SDF) imaging for measuring the perfused boundary region (PBR) in the sublingual capillary bed. a Recording of the
sublingual capillary bed captured using an SDF camera (left). The capillaries are automatically recognized and analyzed after various quality checks
(right). Based on the shift in the red blood cell (RBC) column width over time, the PBR can be calculated. b Model of a blood vessel showing the
PBR under healthy conditions (left). The EG prevents the RBC from approaching the endothelial cell; thus, the PBR is relatively small. Under disease
conditions (right) or after enzymatic breakdown of the EG in an animal model, the damaged EG allows the RBCs to approach the endothelium
more often. This results in a higher variation in RBC column width, which is reflected as a high PBR. ESL, endothelial surface layer (cited from
Dane MJ, van den Berg BM, et al. Am J Physiol Renal Physiol. 2015,308(9):F956–F966)
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can be used to demarcate the GCX layer. Several clinical
studies have been reported, and changes in the GCX
layer have been confirmed using this technique [66].
Sidestream dark field imaging is a unique measurement
for assessing damage to the GCX in situ. This measure-
ment observes superficial vessels (sublingual vessels) and
the red blood cell stream simultaneously (Fig. 5). An ex-
clusion space exists between the vessel wall surface and
the red blood cell stream. The width of this space corre-
sponds to the thickness of the GCX or ESL. This system
can be used to estimate GCX damage in patients. Several
clinical reports have already been published, and signifi-
cant illness-induced changes in GCX thickness have been
reported [67]. Patients who have undergone cardiopulmo-
nary bypass (CPB) have a thinner GCX in sublingual ves-
sels, suggesting that CPB might damage the GCX [58, 68].
Pharmacological preservation and intervention
Since GCX degradation is strongly correlated with disease
progression, pharmacological intervention to prevent GCX
degradation has been widely considered (Table 3). Hyper-
permeability and thrombotic activation may be targets of
such interventions. HA is expected to help repair damaged
GCX [69]. Sulodexide is a highly purified mixture of GAGs
composed of low molecular weight heparin (80 %) and der-
matan sulfate (20 %). Sulodexide has been used to treat pa-
tients with type 2 diabetes mellitus, and a restoration of the
GCX thickness was shown [67]. Antithrombin and hydro-
cortisone have been reported to prevent the ischemia-
induced release of HA and syndecan-1 [70, 71]. Immobiliz-
ing multi-arm heparin has also been used in an animal
model to prevent thrombin formation and to protect the
ESL during the induction of ischemic reperfusion injury
(IRI) [72].
Hydroxyethyl starch has been reported to prevent capil-
lary leakage [73], and its mechanism is assumed to have a
plugging effect on ESL pores caused by GCX degradation
[74, 75]. Whether the mechanism involves plugging or a
specific interaction with the GCX remains uncertain [76].
Hydrocortisone is expected to reduce GCX damage
[70]; this result has been obtained in an animal
model, which also exhibited a reduction in sydecan-1
release, and tissue edema. Further experiments have
shown that this mechanism involves the prevention of
IRI-induced platelet adhesion [77, 78]. Sevoflurane
also has a protective effect on the GCX by preventing
IRI-induced leukocyte and platelet adhesion [79, 80].
Atrial natriuretic hormone (ANP) is assumed to
cause the GCX shedding. ANP is excreted from the
atrium and plays a role in regulating the intravascular
volume. Physiological levels of this peptide have been
shown to result in the GCX shedding and the promo-
tion of vascular leakage [81]. Hypervolemia itself trig-
gers ANP excretion. Since hypervolemia is harmful to
thin layers, such as in the lung or other organs, ex-
cessive water should be drained. ANP may act to
open water channels to the interstitium, resulting in
the efflux of water [82]. Whether ANP is a regulator
of the strength of the GCX seal or the disruption of
the GCX is uncertain. In this context, matrix metallo-
protease has been experimentally shown to reduce
GCX damage. This pathway has also attracted atten-
tion in terms of protecting the GCX.
Although pharmacological intervention to GCX is
widely challenged, the physiological synthesis and turn-
over has not been elucidated. There may be a key point
to preserve and protect GCX from various kind of in-
jury. Albumin has been shown to reduce GCX shedding
caused by cold ischemia [83]. Also fresh frozen plasma
(FFP) has been shown to protect vascular endothelial
permeability [84]. GCX layer is coated by albumin and
proteins; thus, these natural components may not only
constitute the barrier against flowing substances but
may nourish GCX. Schött et al. hypothesize that FFP
may inhibit or neutralize sheddases (a diverse group of
proteases) and/or that FFP mobilizes intracellular stores
of preformed syndecans [85]. Further research to eluci-
date natural turn-over of GCX may disclose the theoret-
ical protection of GCX.
Table 3 Pharmacological intervention for GCX protection
Authors Study subjects Substances Insults Results
Broekhuizen [67] Patients Sulodexide Diabetes mellitus type 2 GCX thickness increased
Gao [71] Rats Hydrocortisone Pancreatitis Improved intestinal perfusion
Attenuation of Syn-1 and HA release
Nordling [72] Endothelial cells Immobilized heparin conjugate IRI Attenuation of thrombotic disorder
Strunden [75] Isolated mouse lung HES Heparinase HES attenuated interstitial edema,
increased pulmonary arterial pressure
Chappell [70] Isolated guinea pig heart Corticosteroid IRI Increase in Syn-1 and reduction in HS
Chappell [79] Isolated guinea pig heart Sevoflurane IRI Increase in Syn-1 and reduction in HS
IRI ischemia reperfusion injury
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Conclusions
The GCX is an extracellular matrix that covers the lu-
minal surface of the vascular system. This structure is
not just a barrier for vascular permeability but contrib-
utes to various functions including signal sensing and
transmission to the endothelium. Thus, pathological
changes to this structure are involved in the develop-
ment of various diseases. Further research on the GCX
is expected to provide useful information for the regula-
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